<unk> , sold under the brand name Jalyn among others, is a medication produced by GlaxoSmithKline for the treatment of adult male symptomatic benign prostatic hyperplasia (BPH). It is a combination of two previously existing medications:<unk> , brand name Avodart, and<unk> , brand name Flomax. It contains 0.5 mg of<unk>  and 0.4 mg of<unk>  hydrochloride. Jalyn was the result of the CombAT (Combination of Avodart and<unk>  trial of 2008. It was approved by the U.S. Food and Drug Administration (FDA) on June 14, 2010. In June 2011, the FDA approved a label change warning of "Increased Risk of High-grade Prostate Cancer" from Jalyn.
Dutasteride/tamsulosin
Finasteride/tadalafil
Finasteride
Drospirenone/estetrol
Indacaterol/mometasone
Indacaterol/glycopyrronium bromide/mometasone
Tadalafil
Relugolix/estradiol/norethisterone acetate